MedTrace Logo

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

NCT05758610 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-05-08

No results posted yet for this study

Summary

This Trial is an open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with AML and NHL who previously received standard treatment or are ineligible for standard treatment options.

Conditions

  • NHL, Adult
  • AML, Adult Recurrent

Interventions

DRUG

ETH-155008

ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor. Dosage form: 10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal.

Sponsors & Collaborators

  • Shengke Pharmaceuticals (Jiangsu) Limited, China

    lead INDUSTRY

Principal Investigators

  • James Zhang · Shengke Pharmaceuticals (Jiangsu) Limited, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-04
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05758610 on ClinicalTrials.gov